Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Weak Angiomax sales hit Medicines Company Q1 expectations

This article was originally published in Scrip

Executive Summary

The Medicines Company is expecting weak first quarter total net revenues thanks to lower sales of Angiomax (bivalirudin), says the firm. It now expects net revenues for the anticoagulant of between $97m and $105m, down from $155.7m in the first quarter of 2014. Total net revenues are likely to reach between $125m and $130m, which marks a 26-29% drop on last year's first quarter revenues of $177.2m. The firm blames the decline on uncertainty over Angiomax's patent exclusivity in the US past June 2015 when a final decision on Hospira's patent challenge is expected. Analysts at Jefferies have reduced their price target for the firm from $27 to $26. Final first quarter results will be released in May.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC028399

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel